The contact activation inhibitor and factor XI antibody, AB023, produces safe, dose-dependent anticoagulation in a phase 1 first-in-human trial

OBJECTIVE: Factor XI (FXI) contributes to thrombotic disease while playing a limited role in normal hemostasis. We generated a unique, humanized anti-FXI antibody, AB023, which blocks factor XIIa (FXIIa)-mediated FXI activation without inhibiting FXI activation by thrombin or the procoagulant functi...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Arterioscler Thromb Vasc Biol
Auteurs principaux: Lorentz, Christina U., Verbout, Norah G., Wallisch, Michael, Hagen, Matthew W., Shatzel, Joseph J., Olson, Sven R., Puy, Cristina, Hinds, Monica T., McCarty, Owen J.T., Gailani, David, Gruber, András, Tucker, Erik. I.
Format: Artigo
Langue:Inglês
Publié: 2019
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6494446/
https://ncbi.nlm.nih.gov/pubmed/30700130
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/ATVBAHA.118.312328
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires